Press release content from Accesswire. The AP news staff was not involved in its creation.
Aytu BioPharma Adds Late-Stage Pediatric Onset Rare Disease Asset to Development Pipeline from Rumpus Therapeutics
April 12, 2021 GMT
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indicationsProgram initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue ...
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indicationsProgram initially targeting vascular Ehlers-Danlos Syndrome (vEDS), a rare inherited connective tissue ...
Aytu gains global license to pivotal study-ready protein kinase C β isoform (PKCβ) inhibitor, AR101 (enzastaurin) in rare disease indications